Protocol
Two green kiwifruit a day for constipation
In a randomized crossover A trial design in which each participant receives both the treatment and the comparison, one after the other, and serves as their own control. trial of 184 people, two green kiwifruit a day for 4 weeks increased complete bowel movements by about 1.5 a week in functional constipation and constipation-predominant IBS, compared with baseline, with better gut comfort; the comparison treatment was psyllium.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
Two green kiwifruit a day for four weeks gave people with constipation about one and a half more full bowel movements a week and less discomfort. The main trial compared kiwifruit with a fiber supplement. A kiwifruit company sponsored the main trial.
- What was measured
- The number of complete bowel movements per week, from diaries over 4 weeks.
- How big
- About 1.5 more complete bowel movements a week in functional constipation and IBS-C.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 36537785.
- Who it applies to
- Adults with functional constipation or IBS-C.
- Safety
- No serious side effects were reported.
- Compared with
- Psyllium fiber 7.5 g a day, in crossover.
- Certainty
- Grade C, resting on: One randomized crossover trial and one exploratory partially randomized trial.
- What would change this grade
- Could rise to B with: Randomized trial of kiwifruit against a placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. food. Who: Adults with chronic constipation. Measured: Complete spontaneous bowel movements per week. Length: At least 4 weeks.
- Cost
- No price recorded yet.
- Sources
- 2 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In a randomized crossover trial of 184 people, two green kiwifruit a day for 4 weeks increased complete bowel movements by about 1.5 a week in functional constipation and constipation-predominant IBS, compared with baseline, with better gut comfort; the comparison treatment was psyllium. A second US trial was only partly randomized and exploratory, so the result stands as one trial and the letter is C.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on bowel movements in constipation. One randomized crossover trial of 184 people found about 1.5 more complete bowel movements a week from baseline with two kiwifruit daily (Gearry et al., 2023; PMID 36537785).
WHY NOT Bthe supporting US trial was partly randomized and explicitly exploratory (Chey et al., 2021; PMID 34074830), so the result has no independent replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.; the endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. is self-reported from bowel diaries, and the comparator was psyllium, not a placebo. FUNDING: the main trial was sponsored and funded by Zespri International, a kiwifruit marketer, which reviewed and approved the study design.
WHAT THIS GRADE DOES NOT COVERgold kiwifruit, kiwifruit extracts and powders, and constipation caused by medicines, none of which this trial tested.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint graded: Number of complete spontaneous bowel movements per week (self_report)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
An independent, fully randomized replication would carry the letter to B.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Kiwifruit among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Kiwifruit on ClinicalTrials.gov
Dose, form and timing
The number of complete bowel movements per week, and straining.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 444 · November 2026 · First graded.
New record in the food section. In a randomized crossover trial of 184 people, two green kiwifruit a day for 4 weeks increased complete bowel movements by about 1.5 a week in functional constipation and constipation-predominant IBS, compared with baseline, with better gut comfort; the comparison treatment was psyllium. A second US trial was only partly randomized and exploratory, so the result stands as one trial and the letter is C.PMID 36537785 PMID 34074830
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullTwo papers, each linked to its PubMed record.
Gearry et al. (Am J Gastroenterol, 2023; PMID 36537785): randomized AB/BA crossover trial, 184 participants (63 healthy, 60 functional constipation, 61 IBS-C), 2 green kiwifruit or psyllium 7.5 g daily for 4 weeks each; kiwifruit increased complete spontaneous bowel movements by 1.53 per week in functional constipation and 1.73 in IBS-C from baseline and improved GI comfort. Chey et al. (Am J Gastroenterol, 2021; PMID 34074830): exploratory partially randomized trial, 79 US patients with chronic constipation; kiwifruit, prunes and psyllium all increased bowel movements; kiwifruit had the fewest adverse events.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(kiwifruit[tiab] OR kiwi[tiab]) AND (constipation[tiab] OR bowel[tiab]) AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Gearry et al., 2023, Am J Gastroenterol (PMID 36537785): PubMed lists no funder for this trial. The PubMed record carries a competing-interest statement.
- Chey et al., 2021, Am J Gastroenterol (PMID 34074830): PubMed lists no funder for this trial.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →